News
Touchlight receives funding to develeop DNA vaccine platform
Touchlight – a company which focuses on genetic medicine revolution – is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Touchlight – a company which focuses on genetic medicine revolution – is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform.